Changes in the Fungal Marker β-D-Glucan After Antiretroviral Therapy and Association With Adiposity.

ABSTRACT:

Background

Bacterial translocation in HIV is associated with inflammation and metabolic complications; few data exist on the role of fungal translocation.

Methods

A5260s was a substudy of A5257, a prospective open label randomized trial in which treatment-naïve people with HIV (PWH) were randomized to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ritonavir (DRV/r), or raltegravir (RAL) over 96 weeks. Baseline was assessed, and changes in β-D-glucan (BDG) were assessed at weeks 4, 24, and 96. Wilcoxon rank-sum tests were used to compare distribution shifts in the changes from baseline between treatment arms and linear regression models to assess associations between BDG and measures of inflammation, body composition, and insulin resistance.

SUBMITTER: Dirajlal-Fargo S 

PROVIDER: S-EPMC6847395 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature